HANOI, May 27 (Reuters) - French pharmaceutical company Sanofi (SASY.PA), opens new tab said on Tuesday it was exploring opportunities for producing vaccines in Vietnam in cooperation with local ...

May 22 (Reuters) - Sanofi (SASY.PA), opens new tab will acquire Vigil Neuroscience (VIGL.O), opens new tab, a clinical-stage biotech company in a $470 million deal, the companies said on Thursday ...

In the wake of the COVID-19 pandemic, which acclimated many workers to at-home or hybrid work models, French drugmaker Sanofi concluded that the traditional office paradigm was on its way out.

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its early-stage neurology pipeline. Sanofi announced via a news release dated May ...

Sanofi SAN0.61%increase; green up pointing triangle said it entered an agreement to acquire Vigil Neuroscience VIGL-0.25%decrease; red down pointing triangle for approximately $470 million, a deal ...

CFOTO / Future Publishing via Getty Images A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.

Recent research from Sanofi highlights the significant impact of Type 1 Diabetes on those living with the condition The song, "Rise Up," shares their experiences of living with the condition and ...

Sanofi to acquire Vigil Neuroscience for up to $600M, including a $2/share CVR tied to VG-3927 milestones. VG-3927, a once-daily oral TREM2 agonist for Alzheimer’s, to enter Phase 2; VGL101 ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...

Additionally, Sanofi will also pay Vigil shareholders $2 per share in cash on the first commercial sale of its Alzheimer’s drug- VG-3927. VG-3927 is an early-stage drug that is set to be ...

Regeneron and Sanofi will review the data and discuss it with regulatory authorities to evaluate the next steps. Itepekimab is also being evaluated in other respiratory conditions, including ...

Paris, May 22, 2025. Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on ...